Physiomics PLC Physiomics awarded contract by Astellas Pharma Inc (6823U)
31 Julio 2020 - 01:00AM
UK Regulatory
TIDMPYC
RNS Number : 6823U
Physiomics PLC
31 July 2020
31 July 2020
Physiomics plc
("Physiomics") or (the "Company")
Physiomics awarded contract by Astellas Pharma Inc.
Physiomics plc (AIM: PYC), the oncology consultancy using
mathematical models and its Virtual Tumour(TM) technology to
support the development of cancer treatment regimens and
personalised medicine solutions, is pleased to announce that,
further to its announcements of 27 May, 30 June and 22 July 2020,
it has been awarded a contract by a new client, Astellas Pharma
Inc. (TSE: 4503) ("Astellas"), a Japanese global pharmaceutical
company.
The contract is for a modelling project involving Physiomics'
Virtual Tumour(TM) immuno-oncology model and relates to an
undisclosed Astellas asset. The work is expected to be completed
this calendar year. The precise value of the contract cannot be
disclosed for reasons of commercial confidentiality however it is
around 20% of the Company's last full year's total income to the 30
June 2019.
Dr Jim Millen, CEO said : "We are delighted to have been awarded
this contract by Astellas, a global pharmaceutical company with a
strong oncology focus. We look forward to working with this
important new client to support its oncology development
activities."
This announcement is released by Physiomics plc and contains
inside information for the purposes of Article 7 of the Market
Abuse Regulation (EU) 596/2014 (MAR), and is disclosed in
accordance with the Company's obligations under Article 17 of
MAR.
Enquiries:
Physiomics plc
Dr Jim Millen, CEO
+44 (0)1865 784 980
Strand Hanson Ltd (NOMAD)
Richard Tulloch & James Dance
+44 (0) 20 7409 3494
Hybridan LLP (broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Notes to Editor
About Physiomics
Physiomics plc (AIM: PYC ) is an oncology consultancy using
mathematical models to support the development of cancer treatment
regimens and personalised medicine solutions. The Company's Virtual
Tumour(TM) technology uses computer modelling to predict the
effects of cancer drugs and treatments to improve the success rate
of drug discovery and development projects while reducing time and
cost. The predictive capability of Physiomics' technologies have
been confirmed by over 70 projects, involving over 30 targets and
60 drugs, and has worked with clients such as Merck KGaA, Merck
& Co, Bayer and Lilly.
Based in Oxford UK, the Company works with clients worldwide to
support their pre-clinical and clinical oncology development
programs. Its team of scientists and computer modelling experts
provide bespoke solutions encompassing data, analytics and
insight.
Physiomics senior management has academic and commercial
expertise, including over 120 years collectively of working in
oncology and/or computational biology and over 120 publications in
peer reviewed journals that have attracted thousands of
citations.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
CNTFLFEDDIIIVII
(END) Dow Jones Newswires
July 31, 2020 02:00 ET (06:00 GMT)
Physiomics (LSE:PYC)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Physiomics (LSE:PYC)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024